PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

News

Undertreatment of FH still an issue in statin era

Undertreatment of FH still an issue in statin era

Despite widespread statin prescribing, individuals with familial hypercholesterolaemia (FH) are dying earlier from cardiovascular disease than those without FH, according to the results of a Norwegian registry study. Under diagnosis and undertreatment of FH have been highlighted as crucial issues warranting urgent action in the…

read more »
Is there a need for a unified definition for FH?

Is there a need for a unified definition for FH?

2014 FH Global Summit: 13-14 October, New York, USA: FH is clearly underdiagnosed and undertreated in the majority of countries.1 Given this status quo, would the development of a unified global definition of FH offer advantages for detection, management and health policy? In the FH…

read more »
PCSK9 variants associated with cerebral ischaemic stroke in Han Chinese

PCSK9 variants associated with cerebral ischaemic stroke in Han Chinese

PCSK9 variants have been previously linked with risk for cerebrovascular disease in Caucasian populations.1 Given the propensity for stroke in Asians, notably the Chinese,2 the current study investigated whether PCSK9 variants may be implicated with risk for stroke in the Han Chinese population. The study…

read more »
Very low LDL-C levels and risk for haemorrhagic complications after ischaemic stroke: should we be worried with PCSK9-targeted therapy?

Very low LDL-C levels and risk for haemorrhagic complications after ischaemic stroke: should we be worried with PCSK9-targeted therapy?

Results from this experimental model suggests that PCSK9 inhibition is unlikely to increase the risk of haemorrhagic complications after ischaemic stroke. Haemorrhagic transformation, a spectrum of ischaemia-related brain haemorrhage, is a complication of acute ischaemic stroke that occurs in 10-40% of patients, and is associated…

read more »
PCSK9 inhibition reduces atherosclerosis development

PCSK9 inhibition reduces atherosclerosis development

Exciting results from an animal study show that a monoclonal antibody to PCSK9, alirocumab, reduces atherosclerosis development. This study used an experimental model of dyslipidaemia and atherosclerosis (APOE*3Leiden.CETP mice) fed a Western-type diet. The mice were treated with alirocumab (3 or 10 mg/kg, weekly subcutaneous…

read more »
ACC 2014 Alirocumab: One-year data in heterozygous FH

ACC 2014 Alirocumab: One-year data in heterozygous FH

Treatment with the PCSK9 monoclonal antibody alirocumab 150 mg every 2 weeks, in addition to statin±ezetimibe,  resulted in substantial LDL-C reductions in patients with heterozygous FH, consistent with phase II trial data, which were sustained over 12 months. These data extend the evidence for the…

read more »
JUPITER Lp(a) analysis and residual CV risk

JUPITER Lp(a) analysis and residual CV risk

This analysis from the JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) in individuals with low LDL cholesterol and elevated high-sensivity C-reactive protein levels suggests that elevated Lp(a) is a contributor to lipid-related residual CV risk. The study…

read more »